Dolby Laboratories filings document the regulatory disclosures of a technology licensing and cinema-products company whose Class A common stock trades on the New York Stock Exchange under DLB. Recent Form 8-K reports furnish quarterly and annual financial results, dividend declarations for Class A and Class B common stock, and related exhibits.
The company’s proxy and governance filings cover director elections, advisory executive-compensation votes, auditor ratification and executive incentive compensation arrangements. The filings also describe Dolby’s dual-class voting structure, with Class A and Class B common stock voting together on most stockholder matters except where law requires otherwise.
Dolby Laboratories executive reports stock option exercise and sale. On 12/01/2025, EVP, General Counsel & Secretary Mark Andrew Sherman exercised an employee stock option for 4,500 shares of Dolby Class A common stock at an exercise price of $64.6 per share and acquired these shares.
On the same date, he sold 4,500 shares of Class A common stock at a weighted average price of $67.5635 per share in multiple transactions. Following these transactions, he beneficially owned 62,397 shares of Class A common stock, which include 45,470 shares underlying restricted stock units that remain subject to forfeiture until they vest.
Dolby Laboratories insider plans Rule 144 share sale. A holder has filed a notice to sell 4,500 shares of common stock of Dolby Laboratories under Rule 144. The proposed sale, through Morgan Stanley Smith Barney LLC on the NYSE, has an aggregate market value of $304,035.75 based on the filing information. The shares were acquired on 12/01/2025 via a stock option exercise from the issuer for cash, and the same number of shares is slated for sale. The filing notes that 60,845,846 shares of the issuer’s common stock were outstanding, providing context for the size of this planned transaction.
Dolby Laboratories, Inc. (DLB) President and CEO Kevin Yeaman, who is also a director, reported multiple transactions in Class A common stock and related stock options. On November 24, 2025, a family trust exercised employee stock options for 25,000 shares at $45.50 and 11,699 shares at $64.60, increasing indirect holdings. That same day, the trust sold 36,699 shares at a weighted average price of $66.9066, with the shares sold in multiple transactions under a Rule 10b5-1 trading plan adopted on February 28, 2025.
On November 26, 2025, Mr. Yeaman gifted 16,348 shares of Class A common stock from the trust to a donor-advised fund for charitable purposes. Following the reported transactions, indirect holdings include 98,377 shares in the family trust and additional indirect ownership through restricted stock units and shares held by a son.
Dolby Laboratories, Inc. (DLB) reported an insider stock sale by a director. On 11/25/2025, a director sold 3,300 shares of Class A common stock in an open market transaction coded "S" at a price of $67.85 per share. After this sale, the director beneficially owned 9,107 shares of Class A common stock.
This remaining amount includes 3,140 shares underlying restricted stock units that are subject to forfeiture until they vest, meaning the director must meet vesting conditions before fully owning those shares.
Dolby Laboratories (DLB) has a planned sale of restricted common stock under Rule 144. The notice covers the proposed sale of 3,300 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $223,905.00. The issuer has 60,845,846 shares of common stock outstanding.
The seller acquired these shares as restricted stock directly from the issuer in two grants: 2,783 shares on 02/06/2023 and 517 shares on 02/05/2024, both noted as not involving special payment arrangements. The approximate date of sale listed in the notice is 11/25/2025.
Dolby Laboratories, Inc. insider activity: A company officer, identified as SVP of the Advanced Technology Group, reported selling 3,000 shares of Dolby Laboratories Class A common stock on 11/21/2025 at a price of $65.55 per share. After this transaction, the reporting person beneficially owns 67,435 shares of Class A common stock.
The remaining holdings include 47,766 shares underlying restricted stock units that may be forfeited if they do not vest, meaning a substantial portion of the reported ownership is still subject to vesting conditions over time.
Dolby Laboratories (DLB) senior vice president of entertainment reported a sale of Class A common stock. On 11/20/2025, the executive sold 6,164 shares of Dolby Class A common stock at a price of $66.12 per share. After this transaction, the executive beneficially owns 115,338 shares of Class A common stock. This total includes 48,526 shares underlying restricted stock units that may be forfeited if they do not vest, as well as 284 shares and 67 shares acquired through the company’s Employee Stock Purchase Plan on May 15, 2025 and November 17, 2025.
Dolby Laboratories (DLB) has a Form 144 notice indicating a planned sale of 36,699 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $2,455,401.64. The filing notes that 60,845,846 shares of common stock are outstanding.
The shares to be sold were acquired on 11/24/2025 via a stock option exercise from the issuer, paid in cash, on the same date. Over the past three months, the Yeaman Family Trust sold 25,000 common shares on 10/14/2025 for gross proceeds of $1,721,840.00 and another 25,000 shares on 09/16/2025 for $1,791,487.50. The signatory represents that they are not aware of undisclosed material adverse information about Dolby’s operations.
An insider of DLB has filed a Form 144 indicating an intent to sell up to 3,000 shares of common stock through Morgan Stanley Smith Barney, with an aggregate market value of 196,650.00. The shares relate to restricted stock awards acquired from the issuer on 05/16/2023 and 05/16/2024, totaling 2,279 and 721 shares respectively, both noted as not involving special payment terms. The notice lists 60,845,846 shares of the issuer’s common stock outstanding and targets an approximate sale date of 11/21/2025 on the NYSE. Over the prior three months, the same seller disposed of 7,000 shares of common stock on 08/22/2025 for gross proceeds of 524,440.00.
Dolby Laboratories (DLB) filed a Form 144 indicating a planned sale of restricted stock. The notice covers the proposed sale of 6,164 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $407,563.68. The filing notes that 60,845,846 shares of the issuer’s common stock are outstanding.
The shares to be sold were originally acquired as restricted stock from the issuer in multiple grants between 2013 and 2021, including blocks of 2,356 shares on 12/15/2020 and 1,627 shares on 12/16/2021, all listed as fully paid in cash or not requiring additional consideration. The person on whose behalf the sale is planned represents that they are not aware of any undisclosed material adverse information about the company’s operations.